Perrigo

Perrigo

PRGO
Dublin, Ireland· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

PRGO · Stock Price

USD 11.72-15.27 (-56.58%)
Market Cap: $1.6B

Historical price data

Market Cap: $1.6BPipeline: 7 drugsFounded: 1887HQ: Dublin, Ireland

Overview

Perrigo's mission is to make lives better by providing trusted, accessible health and wellness solutions to all. The company has evolved from its 1887 origins into a multinational enterprise with a core strategy of delivering value through private-label manufacturing and select branded products. Its achievements include building a robust, diversified portfolio in essential self-care categories and maintaining a resilient supply chain. Perrigo's strategy focuses on expanding its self-care portfolio, driving operational excellence, and leveraging its formulation and regulatory expertise to capitalize on the growing demand for affordable healthcare.

Self-Care / OTCInfant NutritionVitamins & Supplements

Technology Platform

A vertically-integrated commercialization, formulation, and supply chain platform focused on efficient development, manufacturing, and distribution of bioequivalent OTC drugs, infant nutrition, and consumer health products.

Pipeline

7
7 drugs in pipeline
DrugIndicationStageWatch
Vivomixx + PlaceboBreast CancerPhase 1/2
Famotidine Tablets, 40 mgBioavailabilityPhase 1
Naproxen Tablets, 500 mgBioequivalencyPhase 1
Ibuprofen Tablets, 800 mgBioequivalencyPhase 1
Naproxen Tablets, 500 mgBioequivalencyPhase 1

Funding History

2
Total raised:$800M
Debt$800M
IPOUndisclosed

FDA Approved Drugs

49
NASONEX 24HR ALLERGYNDAMar 17, 2022
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDEANDAFeb 1, 2022
FEXOFENADINE HYDROCHLORIDEANDAFeb 24, 2020

Opportunities

Perrigo is well-positioned to capitalize on the global trend towards value-conscious self-care and the growth of retailer private-label programs.
Expansion in infant nutrition and strategic acquisitions in core OTC categories present specific growth vectors.

Risk Factors

Key risks include intense pricing pressure in generics, customer concentration with large retailers, regulatory compliance for manufacturing, and sensitivity to commodity and supply chain costs.

Competitive Landscape

Perrigo competes with branded giants (J&J, Bayer, GSK) in consumer health and with large generic manufacturers (Teva, Viatris) in private label. Its hybrid model of owning brands and manufacturing for retailers is its primary differentiator.

Company Timeline

1887Founded

Founded in Dublin, Ireland

1991IPO

Initial Public Offering

2013Debt

Debt: $800.0M

2020FDA Approval

FDA Approval: FEXOFENADINE HYDROCHLORIDE

2022FDA Approval

FDA Approval: NASONEX 24HR ALLERGY

2022FDA Approval

FDA Approval: GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE